Qyuns Therapeutics Co., Ltd. Class H (HK:2509) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Qyuns Therapeutics Co., Ltd. has announced that its supplemental application for the use of Ustekinumab Injection (QX001S) in treating pediatric plaque psoriasis has been accepted. This biosimilar drug, developed to mimic Johnson & Johnson’s Stelara, is already approved for various conditions, including adult plaque psoriasis. With this development, Qyuns Therapeutics seeks to expand its market influence in the treatment of immune-mediated inflammatory diseases.
For further insights into HK:2509 stock, check out TipRanks’ Stock Analysis page.